팝업레이어 알림

팝업레이어 알림이 없습니다.

뇌질환의 혁신, 뉴로벤티(NeuroVenti)

INNOVATING TREATMENT
FOR BRAIN DEVELOPMENTAL DISORDERS

Development of patient-customized novel
drugs for optimal brain function utilization

DISCOVERING CANDIDATES FOR
OPTIMIZED BRAIN DISEASE TREATMENT

Provision of customized solutions
for intractable brain diseases

INTEGRATING PLATFORMS
OF TREATMENT
FOR BRAIN DISEASES

Holistic approach to brain well-being
from cradle to grave

NeuroVenti

NeuroVenti is a global biotech startup
leading the development of neuroprotective
and therapeutic agents against neuronal disorders.

자폐증 치료제 후보물질(NV01-A02)의 FDA 희귀의약품 지정에 성공한 뉴로벤티는 임상 2상 준비중으로, 비임상 CDRO도 제공하고 있습니다

Read More

Pipeline

Introduce the pipeline of NeuroVenti

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-A02

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-A03

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-O62

R&D Services

Introducing NeuroVenti's core research capabilities

- A variety of neurological disease models, in vivo and in vitro efficacy assessment system, and a system for mechanistic studies
- Establish the best research plan for your needs through the preclinical research consulting
- Select models, preliminary experiments, and establish evaluation methods through consultation after applying collaboration and research services
- Provide customer-oriented and optimized evaluation services

View More

News

NeuroVenti Promotes CDRO Service Successfully…

Adding know-how to the existing CRO service, we are proud of the highest level in Korea in the CNS field  &nbs…
NeuroVenti Promotes CDRO Service Successfully…

'Exhibition of masterpieces that light up the…

'Exhibition of masterpieces that light up the world', participation of executives and employees of NeuroVentiNeuroVenti …
'Exhibition of masterpieces that light up the…

2024 World Autism Day, NeuroVenti was also wi…

2024 World Autism Day, NeuroVenti was also with us.It's a day when all autistic people in the world become the main char…
2024 World Autism Day, NeuroVenti was also wi…

Kwon Kyoung Ja, director of NeuroVenti, lectu…

Kwon Kyoung Ja, director of NeuroVenti, lectures at the 2024 Spring Conference of the Korean Association of Applied Drug…
Kwon Kyoung Ja, director of NeuroVenti, lectu…

Oxytocin receptor is not required for social …

Prairie voles are among a small group of mammals that display long-term social attachment between mating partners. Many…
이미지없음

Screening and services for autism among child…

In 2016, the prevalence of autism spectrum disorder in China among children aged 6–12 years was approximately 0·7% (an e…
이미지없음

Genomic architecture of autism from comprehen…

Fully understanding autism spectrum disorder (ASD) genetics requires whole-genome sequencing (WGS). We present the lates…
이미지없음

Analysis of difference in eye contact and bra…

Reluctance to make eye contact during natural interactions is a central diagnostic criterion for autism spectrum disorde…
이미지없음

Business area

Realizing Brain Wellness Society through Treatment of Neurodevelopmental Disorders
and Intractable Neurological Diseases, and Optimal Utilization of Brain Function

Drug
Development
CNS disorders’
therapeutic
candidates
research service
Platform
technology